preclinical work with reovirus in combination with radiation, and
reovirus administration following cyclophosphamide.
- In April, two presentations were made at the American Association for
Cancer Research (AACR) covering work using the reovirus in
combination with radiation for pediatric sarcomas, and reovirus as a
purging agent for autologous stem cell transplants.
- In April, a paper covering preclinical work demonstrating that
reovirus can kill melanoma cell lines and freshly resected tumour was
published in Gene Therapy.
- Two Canadian patents and one U.S. patent were secured in the quarter.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
This discussion and analysis should be read in conjunction with the unaudited consolidated financial statements of Oncolytics Biotech Inc. as at and for the three months ended March 31, 2008 and 2007, and should also be read in conjunction with the audited financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") contained in our annual report for the year ended December 31, 2007. The financial statements have been prepared in accordance with Canadian generally accepted accounting principles ("GAAP").
The following discussion contains forward-looking statements, within
the meaning of Section 21E of the Securities Exchange Act of 1934, as
amended. Forward-looking statements, including our belief as to the
potential of REOLYSIN(R) as a cancer therapeutic and our expectations as to
the success of our research and development and manufacturing programs in
2008 and beyond, future financial position, business strategy and plans for
future operations, and statements t
|SOURCE Oncolytics Biotech Inc.|
Copyright©2008 PR Newswire.
All rights reserved